Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The immunogenicity of a heterologous vaccination regimen consisting of ChAdOx1 nCoV-19 (a chimpanzee adenovirus-vectored vaccine) followed by mRNA-1273 (a lipid–nanoparticle-encapsulated mRNA-based vaccine) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the omicron variant (B.1.1.529), is poorly studied. The aim of this study was to evaluate the neutralizing antibody activity and immunogenicity of heterologous ChAdOx1 nCoV-19 and mRNA-1273 prime-boost vaccination against wild-type (BetaCoV/Korea/KCDC03/2020), alpha, beta, gamma, delta, and omicron variants of SARS-CoV-2 in Korea. A 50% neutralizing dilution (ND50) titer was determined in serum samples using the plaque reduction neutralization test. Antibody titer decreased significantly at 3 months compared with that at 2 weeks after the 2nd dose. On comparing the ND50 titers for the above-mentioned variants of concerns, it was observed that the ND50 titer for the omicron variant was the lowest. This study provides insights into cross-vaccination effects and can be useful for further vaccination strategies in Korea.
Abstract
The immunogenicity of a heterologous vaccination regimen consisting of ChAdOx1 nCoV-19 (a chimpanzee adenovirus-vectored vaccine) followed by mRNA-1273 (a lipid–nanoparticle-encapsulated mRNA-based vaccine) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically the omicron variant (B.1.1.529), is poorly studied. The aim of this study was to evaluate the neutralizing antibody activity and immunogenicity of heterologous ChAdOx1 nCoV-19 and mRNA-1273 prime-boost vaccination against wild-type (BetaCoV/Korea/KCDC03/2020), alpha, beta, gamma, delta, and omicron variants of SARS-CoV-2 in Korea. A 50% neutralizing dilution (ND50) titer was determined in serum samples using the plaque reduction neutralization test. Antibody titer decreased significantly at 3 months compared with that at 2 weeks after the 2nd dose. On comparing the ND50 titers for the above-mentioned variants of concerns, it was observed that the ND50 titer for the omicron variant was the lowest. This study provides insights into cross-vaccination effects and can be useful for further vaccination strategies in Korea.
참고문헌 (19)
- "Statement for healthcare professionals: How COVID-19 vaccines are regulated for safety and effectiveness (Revised March 2022)"[URL]
- 정재훈, "Preparing for the Coronavirus Disease (COVID-19) Vaccination: Evidence, Plans, and Implications", Journal of Korean Medical Science, 36(7), pp.1~20 (2021), 대한의학회[DOI]
- "Coronavirus vaccine tracker"[URL]
- Ramasamy MN, "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2", 3 trial, 2021, pp.396, 1979~1993
- Sadoff J, "Safety and Efficacy of single-dose Ad26. COV2. S vaccine against Covid-19", N Engl J Med, 384, pp.2187~2201 (2021)
- Walsh EE, "Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates", N Engl J Med, 383, pp.2439~2450 (2020)
- Heath PT, "Safety and efficacy of NVX-CoV2373 Covid-19 vaccine", N Engl J Med, 385, pp.1172~1183 (2021)
- "Government to approve SK Bioscience's Covid-19 vaccine this week"[URL]
- Wise J, "Covid-19 : European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots", BMJ, 372, pp.n699~ (2021)
- Normark J, "Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination", N Engl J Med, 385, pp.1049~1051 (2021)
- Deming ME, "A ‘mix and match’ approach to SARS-CoV-2 vaccination", Nat Med, 27, pp.1510~1511 (2021)
- Wan Beom Park, "Virus Isolation from the First Patient with SARS-CoV-2 in Korea", Journal of Korean Medical Science, 35(7), pp.1~5 (2020), 대한의학회[DOI]
- Rose R, "Humoral immune response after different SARS-CoV-2 vaccination regimens", BMC Med, 20, pp.31~ (2022)
- Barros-Martins J, "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19", BNT162b2 vaccination, 2021, pp.27, 1525~1529
- Bae S, "Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity", Clin Microbiol Infect, 28, pp.1390~ (2022)
- Nordström P, "Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden : a nationwide cohort study", Lancet Reg Health Eur, 11, pp.100249~ (2021)
- Jihye Um, "Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults", Journal of Korean Medical Science, 37(9), pp.1~6 (2022), 대한의학회[DOI]
- "New versions of Omicron are masters of immune evasion"[URL]
- Jung MK, "BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality", Nat Microbiol, 7, pp.909~917 (2022)